Honokiol has shown chemopreventive effects in chemically-induced and UVB-induced
skin cancer in mice. In this investigation, we assessed the time-effects of a topical low dose of
honokiol (30 μg), and then the effects of different
honokiol doses (30, 45, and 60 μg) on a UVB-induced
skin cancer model to find an optimal dose and time for desirable chemopreventive effects. UVB radiation (30 mJ/cm(2), 5 days/week for 25 or 27 weeks) was used to induce skin
carcinogenesis in SKH-1 mice. For the time-response experiment 30 μg
honokiol in
acetone was applied topically to the animals before the UVB exposure (30 min, 1 h, and 2 h) and after the UVB exposure (immediately, 30 min, and 1 h). Control groups were treated with
acetone. For the dose-response study, animals were treated topically with
acetone or
honokiol (30, 45, and 60 μg) one hour before the UVB exposure. In the time-response experiment,
honokiol inhibited skin
tumor multiplicity by 49-58% while reducing
tumor volumes by 70-89%. In the dose-response study,
honokiol (30, 45, and 60 μg) significantly decreased skin
tumor multiplicity by 36-78% in a dose-dependent manner, while
tumor area was reduced by 76-94%.
Honokiol (60 μg) significantly reduced
tumor incidence by 40% as compared to control group.
Honokiol applied in very low doses (30 μg) either before or after UVB radiation shows chemopreventive effects.
Honokiol (30, 45, and 60 μg) prevents UVB-induced
skin cancer in a dose-dependent manner.
Honokiol can be an effective chemopreventive agent against
skin cancer.